Vaccines have historically played a pivotal role in reducing the burden of infectious diseases and now play a crucial role in the setting of sexually transmitted infections (STIs). However, there remain several unmet goals: vaccines are available only for viral STIs, vaccination accessibility and uptake remain disproportionate worldwide, and no effective vaccine has been developed for HCV. Moreover, there are no vaccines against bacterial STIs: fewer investments in research have been made, because vaccines are not a top priority due to the availability of effective treatments. However, higher rates of resistance to all available antibiotics has led to a shift in research priorities. Several promising vaccine candidates have been identified or are being investigated in pre-clinical or clinical trials, although further understanding of the immunogenicity, effectiveness and delivery strategies of already licensed vaccines is needed. This paper focuses on current research efforts to develop vaccines against bacterial (e.g. gonorrhoea, chlamydia and syphilis) and viral (e.g. HCV) STIs. We also review current indications and evidence of effectiveness of already available vaccines (e.g. HAV, HBV and HPV) and discuss open issues. ©2022 by EDIMES - Edizioni Internazionali Srl. All rights reserved.

Vaccines against Emerging Sexually Transmitted Infections: Current Preventive Tools and Future Perspectives / Raccagni, Ar; Alberton, F; Castagna, A; Nozza, S. - In: NEW MICROBIOLOGICA. - ISSN 1121-7138. - 45:1(2022), pp. 9-27.

Vaccines against Emerging Sexually Transmitted Infections: Current Preventive Tools and Future Perspectives

Raccagni AR
Co-primo
;
Alberton F
Co-primo
;
Castagna A
Secondo
;
Nozza S
Ultimo
2022-01-01

Abstract

Vaccines have historically played a pivotal role in reducing the burden of infectious diseases and now play a crucial role in the setting of sexually transmitted infections (STIs). However, there remain several unmet goals: vaccines are available only for viral STIs, vaccination accessibility and uptake remain disproportionate worldwide, and no effective vaccine has been developed for HCV. Moreover, there are no vaccines against bacterial STIs: fewer investments in research have been made, because vaccines are not a top priority due to the availability of effective treatments. However, higher rates of resistance to all available antibiotics has led to a shift in research priorities. Several promising vaccine candidates have been identified or are being investigated in pre-clinical or clinical trials, although further understanding of the immunogenicity, effectiveness and delivery strategies of already licensed vaccines is needed. This paper focuses on current research efforts to develop vaccines against bacterial (e.g. gonorrhoea, chlamydia and syphilis) and viral (e.g. HCV) STIs. We also review current indications and evidence of effectiveness of already available vaccines (e.g. HAV, HBV and HPV) and discuss open issues. ©2022 by EDIMES - Edizioni Internazionali Srl. All rights reserved.
2022
Prevention; Sexually Transmitted Infections; Vaccines
File in questo prodotto:
File Dimensione Formato  
MICRO_1_2022_1.2_REVIEW_Raccagni_496N270_009-027.pdf

solo gestori archivio

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Copyright dell'editore
Dimensione 632.53 kB
Formato Adobe PDF
632.53 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/174476
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact